Creative Biolabs is helping researchers overcome challenges of gene therapy research by providing analytical testing ...
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology ...
Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...
OTTAWA, Ontario & YORK, England--(BUSINESS WIRE)--Genvira Biosciences Inc. (“Genvira”), a Canadian innovator in next-generation viral vectors, Labskin Limited (“Labskin”), a leader in 3D in vitro ...
NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
The "Viral Vector Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector Vaccines was estimated at US$773.4 Million in ...
Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results